nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—FGFR2—cleft lip	0.81	1	CbGaD
Thalidomide—FGFR2—skull—cleft lip	0.00617	0.211	CbGeAlD
Thalidomide—NFKB1—mouth—cleft lip	0.00284	0.0972	CbGeAlD
Thalidomide—PTGS2—periosteum—cleft lip	0.00228	0.078	CbGeAlD
Thalidomide—FGFR2—mouth—cleft lip	0.00214	0.073	CbGeAlD
Thalidomide—Menadione—MTHFR—cleft lip	0.00197	1	CrCbGaD
Thalidomide—CRBN—embryo—cleft lip	0.0017	0.0581	CbGeAlD
Thalidomide—NFKB1—telencephalon—cleft lip	0.00165	0.0564	CbGeAlD
Thalidomide—PTGS2—cartilage tissue—cleft lip	0.0016	0.0547	CbGeAlD
Thalidomide—FGFR2—embryo—cleft lip	0.00152	0.0521	CbGeAlD
Thalidomide—CRBN—telencephalon—cleft lip	0.00138	0.0472	CbGeAlD
Thalidomide—FGFR2—telencephalon—cleft lip	0.00124	0.0423	CbGeAlD
Thalidomide—NFKB1—head—cleft lip	0.00103	0.0351	CbGeAlD
Thalidomide—CRBN—head—cleft lip	0.000861	0.0294	CbGeAlD
Thalidomide—CYP1A1—mouth—cleft lip	0.000773	0.0264	CbGeAlD
Thalidomide—FGFR2—head—cleft lip	0.000771	0.0264	CbGeAlD
Thalidomide—PTGS2—mouth—cleft lip	0.000649	0.0222	CbGeAlD
Thalidomide—PTGS2—embryo—cleft lip	0.000463	0.0158	CbGeAlD
Thalidomide—CYP2E1—telencephalon—cleft lip	0.000409	0.014	CbGeAlD
Thalidomide—PTGS1—telencephalon—cleft lip	0.000394	0.0135	CbGeAlD
Thalidomide—PTGS2—telencephalon—cleft lip	0.000376	0.0129	CbGeAlD
Thalidomide—CYP1A1—head—cleft lip	0.000279	0.00954	CbGeAlD
Thalidomide—CYP2E1—head—cleft lip	0.000255	0.0087	CbGeAlD
Thalidomide—PTGS1—head—cleft lip	0.000245	0.00838	CbGeAlD
Thalidomide—PTGS2—head—cleft lip	0.000234	0.00801	CbGeAlD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—FGFR3—cleft lip	9.43e-05	0.000593	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—FGFR1—cleft lip	9.4e-05	0.000591	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—FGFR3—cleft lip	9.39e-05	0.000591	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—MTR—cleft lip	9.37e-05	0.000589	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—FGFR3—cleft lip	9.36e-05	0.000589	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—MTR—cleft lip	9.35e-05	0.000588	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—MYC—cleft lip	9.28e-05	0.000584	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—FGF10—cleft lip	9.25e-05	0.000582	CbGpPWpGaD
Thalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cleft lip	9.2e-05	0.000578	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—cleft lip	9.11e-05	0.000573	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TYMS—cleft lip	9.07e-05	0.000571	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FGF7—cleft lip	9e-05	0.000566	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—FGFR1—cleft lip	9e-05	0.000566	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—FGF2—cleft lip	8.9e-05	0.00056	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—FGFR3—cleft lip	8.88e-05	0.000559	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—MTR—cleft lip	8.84e-05	0.000556	CbGpPWpGaD
Thalidomide—FGFR2—Disease—WNT9B—cleft lip	8.74e-05	0.00055	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—FGF7—cleft lip	8.64e-05	0.000544	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—NOS3—cleft lip	8.58e-05	0.000539	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FGF7—cleft lip	8.54e-05	0.000537	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—FGF2—cleft lip	8.52e-05	0.000536	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—FGF2—cleft lip	8.52e-05	0.000536	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—FGFR1—cleft lip	8.5e-05	0.000535	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—FGFR3—cleft lip	8.5e-05	0.000535	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—FGF2—cleft lip	8.38e-05	0.000527	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IRF6—cleft lip	8.36e-05	0.000526	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FGF8—cleft lip	8.31e-05	0.000523	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Receptor Signaling Pathway—MYC—cleft lip	8.27e-05	0.00052	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—FGF7—cleft lip	8.2e-05	0.000516	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—FGF2—cleft lip	8.19e-05	0.000515	CbGpPWpGaD
Thalidomide—NFKB1—Neural Crest Differentiation—MYC—cleft lip	8.01e-05	0.000504	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—FGF2—cleft lip	8e-05	0.000503	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—FGF8—cleft lip	7.98e-05	0.000502	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—FGF2—cleft lip	7.96e-05	0.000501	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IRF6—cleft lip	7.94e-05	0.000499	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—FGF2—cleft lip	7.92e-05	0.000498	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—FGF2—cleft lip	7.89e-05	0.000496	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FGF8—cleft lip	7.88e-05	0.000496	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—FGFR2—cleft lip	7.82e-05	0.000492	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—FGF2—cleft lip	7.82e-05	0.000492	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ABCA4—cleft lip	7.79e-05	0.00049	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—FGF2—cleft lip	7.77e-05	0.000489	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—FGFR1—cleft lip	7.67e-05	0.000483	CbGpPWpGaD
Thalidomide—FGFR2—Neural Crest Differentiation—MYC—cleft lip	7.6e-05	0.000478	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—FGF8—cleft lip	7.57e-05	0.000476	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—MYC—cleft lip	7.53e-05	0.000474	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—FGF2—cleft lip	7.42e-05	0.000467	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—FGF2—cleft lip	7.42e-05	0.000467	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—FGF2—cleft lip	7.42e-05	0.000467	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	7.36e-05	0.000463	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—FGF2—cleft lip	7.35e-05	0.000462	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—FGFR1—cleft lip	7.29e-05	0.000459	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—FGF2—cleft lip	7.29e-05	0.000458	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—FGF2—cleft lip	7.26e-05	0.000456	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—FGF2—cleft lip	7.24e-05	0.000455	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—MTR—cleft lip	7.23e-05	0.000455	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SLC19A1—cleft lip	7.13e-05	0.000448	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—cleft lip	7.08e-05	0.000445	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—MYC—cleft lip	7.07e-05	0.000445	CbGpPWpGaD
Thalidomide—FGFR2—Disease—WNT3—cleft lip	6.95e-05	0.000437	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—FGFR1—cleft lip	6.92e-05	0.000435	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—FGFR3—cleft lip	6.89e-05	0.000434	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—FGF2—cleft lip	6.87e-05	0.000432	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FGF3—cleft lip	6.76e-05	0.000425	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FGF9—cleft lip	6.59e-05	0.000415	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—MTR—cleft lip	6.59e-05	0.000415	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—FGF2—cleft lip	6.57e-05	0.000413	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—FGFR3—cleft lip	6.54e-05	0.000411	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—FGF3—cleft lip	6.49e-05	0.000408	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—WNT9B—cleft lip	6.45e-05	0.000406	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FGF3—cleft lip	6.42e-05	0.000404	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—FGF9—cleft lip	6.33e-05	0.000398	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—FGF10—cleft lip	6.3e-05	0.000396	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—MYC—cleft lip	6.28e-05	0.000395	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FGF9—cleft lip	6.26e-05	0.000394	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOG—cleft lip	6.19e-05	0.000389	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—FGF3—cleft lip	6.16e-05	0.000388	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—WNT9B—cleft lip	6.12e-05	0.000385	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—FGF9—cleft lip	6.01e-05	0.000378	CbGpPWpGaD
Thalidomide—FGFR2—Ectoderm Differentiation—MYC—cleft lip	5.92e-05	0.000372	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TCN2—cleft lip	5.91e-05	0.000371	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOG—cleft lip	5.87e-05	0.000369	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—MYC—cleft lip	5.8e-05	0.000365	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ABCA4—cleft lip	5.75e-05	0.000362	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SUMO1—cleft lip	5.73e-05	0.000361	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—MTR—cleft lip	5.63e-05	0.000354	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—cleft lip	5.61e-05	0.000353	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	5.61e-05	0.000353	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FGF10—cleft lip	5.56e-05	0.00035	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ABCA4—cleft lip	5.46e-05	0.000343	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SUMO1—cleft lip	5.44e-05	0.000342	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—MYC—cleft lip	5.39e-05	0.000339	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—FGF10—cleft lip	5.34e-05	0.000336	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—MYC—cleft lip	5.33e-05	0.000335	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—FGF2—cleft lip	5.33e-05	0.000335	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FGF10—cleft lip	5.28e-05	0.000332	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGF7—cleft lip	5.24e-05	0.00033	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—WNT3—cleft lip	5.13e-05	0.000322	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—FGF10—cleft lip	5.07e-05	0.000319	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—FGF2—cleft lip	5.05e-05	0.000318	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGF7—cleft lip	4.97e-05	0.000313	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—WNT3—cleft lip	4.86e-05	0.000306	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGF8—cleft lip	4.84e-05	0.000304	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	4.81e-05	0.000303	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—FGF10—cleft lip	4.8e-05	0.000302	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FGFR1—cleft lip	4.75e-05	0.000299	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—FGFR1—cleft lip	4.71e-05	0.000296	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SPRY2—cleft lip	4.59e-05	0.000289	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGF7—cleft lip	4.59e-05	0.000289	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGF8—cleft lip	4.59e-05	0.000289	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FGFR2—cleft lip	4.46e-05	0.000281	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—MYC—cleft lip	4.37e-05	0.000275	CbGpPWpGaD
Thalidomide—PTGS2—Disease—WNT9B—cleft lip	4.34e-05	0.000273	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—FGFR2—cleft lip	4.29e-05	0.00027	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGF8—cleft lip	4.24e-05	0.000267	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FGFR1—cleft lip	4.16e-05	0.000262	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MTR—cleft lip	4.09e-05	0.000257	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—MYC—cleft lip	4.06e-05	0.000255	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—cleft lip	4.01e-05	0.000252	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—FGFR1—cleft lip	3.99e-05	0.000251	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FGFR1—cleft lip	3.95e-05	0.000248	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGF3—cleft lip	3.94e-05	0.000248	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FGFR3—cleft lip	3.93e-05	0.000247	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ABCA4—cleft lip	3.87e-05	0.000243	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGF9—cleft lip	3.84e-05	0.000242	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—FGFR1—cleft lip	3.79e-05	0.000238	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—FGFR3—cleft lip	3.78e-05	0.000237	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGF3—cleft lip	3.74e-05	0.000235	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SLC19A1—cleft lip	3.73e-05	0.000235	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FGFR3—cleft lip	3.73e-05	0.000235	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	3.66e-05	0.00023	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGF9—cleft lip	3.64e-05	0.000229	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—FGFR1—cleft lip	3.59e-05	0.000226	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—FGFR3—cleft lip	3.58e-05	0.000225	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SLC19A1—cleft lip	3.54e-05	0.000223	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	3.47e-05	0.000218	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGF3—cleft lip	3.45e-05	0.000217	CbGpPWpGaD
Thalidomide—PTGS2—Disease—WNT3—cleft lip	3.45e-05	0.000217	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—FGF2—cleft lip	3.44e-05	0.000216	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SPRY2—cleft lip	3.39e-05	0.000213	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGF7—cleft lip	3.39e-05	0.000213	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGF9—cleft lip	3.36e-05	0.000212	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MYC—cleft lip	3.33e-05	0.00021	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGF10—cleft lip	3.24e-05	0.000204	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGF7—cleft lip	3.22e-05	0.000202	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SPRY2—cleft lip	3.22e-05	0.000202	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGF8—cleft lip	3.13e-05	0.000197	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TCN2—cleft lip	3.09e-05	0.000195	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGF10—cleft lip	3.07e-05	0.000193	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FGF2—cleft lip	3.04e-05	0.000191	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGF8—cleft lip	2.97e-05	0.000187	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC19A1—cleft lip	2.96e-05	0.000186	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TCN2—cleft lip	2.93e-05	0.000184	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—FGF2—cleft lip	2.92e-05	0.000184	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FGF2—cleft lip	2.88e-05	0.000181	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGF10—cleft lip	2.84e-05	0.000178	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTCH1—cleft lip	2.81e-05	0.000177	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC19A1—cleft lip	2.79e-05	0.000176	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC19A1—cleft lip	2.78e-05	0.000175	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—FGF2—cleft lip	2.77e-05	0.000174	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTCH1—cleft lip	2.67e-05	0.000168	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC19A1—cleft lip	2.63e-05	0.000165	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—FGF2—cleft lip	2.62e-05	0.000165	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGFR2—cleft lip	2.6e-05	0.000164	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGF3—cleft lip	2.55e-05	0.00016	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGF9—cleft lip	2.48e-05	0.000156	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TCN2—cleft lip	2.46e-05	0.000155	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGFR1—cleft lip	2.42e-05	0.000152	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGF3—cleft lip	2.42e-05	0.000152	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGF9—cleft lip	2.36e-05	0.000148	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TCN2—cleft lip	2.31e-05	0.000145	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TCN2—cleft lip	2.31e-05	0.000145	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGFR1—cleft lip	2.3e-05	0.000145	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGFR3—cleft lip	2.29e-05	0.000144	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SPRY2—cleft lip	2.28e-05	0.000143	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF7—cleft lip	2.28e-05	0.000143	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	2.27e-05	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MTHFR—cleft lip	2.19e-05	0.000138	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TCN2—cleft lip	2.18e-05	0.000137	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGFR3—cleft lip	2.17e-05	0.000137	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC19A1—cleft lip	2.15e-05	0.000135	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTR—cleft lip	2.14e-05	0.000135	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGFR1—cleft lip	2.12e-05	0.000134	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF8—cleft lip	2.1e-05	0.000132	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGF10—cleft lip	2.09e-05	0.000132	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTR—cleft lip	2.03e-05	0.000128	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGFR3—cleft lip	2.01e-05	0.000126	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGF10—cleft lip	1.99e-05	0.000125	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC19A1—cleft lip	1.96e-05	0.000123	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TCN2—cleft lip	1.78e-05	0.000112	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGF2—cleft lip	1.77e-05	0.000111	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF3—cleft lip	1.71e-05	0.000108	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTR—cleft lip	1.7e-05	0.000107	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGFR2—cleft lip	1.68e-05	0.000106	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGF2—cleft lip	1.68e-05	0.000106	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC19A1—cleft lip	1.68e-05	0.000106	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF9—cleft lip	1.67e-05	0.000105	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TCN2—cleft lip	1.63e-05	0.000102	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTR—cleft lip	1.6e-05	0.000101	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTR—cleft lip	1.6e-05	0.000101	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGFR1—cleft lip	1.57e-05	9.85e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGF2—cleft lip	1.55e-05	9.75e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS3—cleft lip	1.53e-05	9.62e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTR—cleft lip	1.51e-05	9.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGFR1—cleft lip	1.49e-05	9.35e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGFR3—cleft lip	1.48e-05	9.31e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF10—cleft lip	1.41e-05	8.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGFR3—cleft lip	1.4e-05	8.84e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TCN2—cleft lip	1.39e-05	8.74e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TYMS—cleft lip	1.31e-05	8.27e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTR—cleft lip	1.24e-05	7.78e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—cleft lip	1.15e-05	7.22e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGF2—cleft lip	1.14e-05	7.2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGFR2—cleft lip	1.13e-05	7.11e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—cleft lip	1.13e-05	7.1e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTR—cleft lip	1.13e-05	7.09e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—cleft lip	1.09e-05	6.85e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGF2—cleft lip	1.09e-05	6.83e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—cleft lip	1.07e-05	6.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGFR1—cleft lip	1.05e-05	6.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TYMS—cleft lip	1.04e-05	6.56e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—cleft lip	1.01e-05	6.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGFR3—cleft lip	9.96e-06	6.27e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TYMS—cleft lip	9.82e-06	6.18e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TYMS—cleft lip	9.8e-06	6.17e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTR—cleft lip	9.63e-06	6.06e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TYMS—cleft lip	9.26e-06	5.83e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—cleft lip	9.12e-06	5.73e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—cleft lip	8.58e-06	5.4e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—cleft lip	8.56e-06	5.39e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—cleft lip	8.09e-06	5.09e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—cleft lip	8.01e-06	5.04e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF2—cleft lip	7.7e-06	4.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—cleft lip	7.59e-06	4.78e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TYMS—cleft lip	7.58e-06	4.77e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—cleft lip	7.48e-06	4.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—cleft lip	7.1e-06	4.46e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TYMS—cleft lip	6.91e-06	4.35e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—cleft lip	6.62e-06	4.16e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—cleft lip	6.36e-06	4e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—cleft lip	6.04e-06	3.8e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—cleft lip	5.99e-06	3.76e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—cleft lip	5.97e-06	3.76e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TYMS—cleft lip	5.91e-06	3.71e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—cleft lip	5.64e-06	3.55e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—cleft lip	5.16e-06	3.24e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—cleft lip	5.03e-06	3.17e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—cleft lip	4.62e-06	2.9e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—cleft lip	4.21e-06	2.65e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—cleft lip	3.6e-06	2.26e-05	CbGpPWpGaD
